Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967042 | 0.89 | MEN1 (0.55) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL9966932 | 0.88 | MEN1 (0.51) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL15456289 | 0.87 | MEN1 (0.41) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL9967037 | 0.87 | MEN1 (0.50) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL9966952 | 0.86 | MEN1 (0.49) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL9967148 | 0.86 | AKT1 (0.45) | AKT1ALDH1A1CNR1CNR2 | |
| SCHEMBL15459822 | 0.85 | MEN1 (0.48) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL15456693 | 0.83 | MEN1 (0.37) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL9967213 | 0.83 | MEN1 (0.46) | MEN1KMT2AAKT1ALDH1A1CNR1 | |
| SCHEMBL15456340 | 0.83 | LRRK2 (0.41) | MEN1KMT2AAKT1ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MEN1 2070/4885KMT2A 2342/4885AKT1 339/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MEN1 2070/4885KMT2A 2342/4885AKT1 339/4885 |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MEN1 2070/4885KMT2A 2342/4885AKT1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.